Secondly, further in vivo and in vitro functional studies are warranted in order to identify the exact molecular mechanism(s) underlying the CDCA5 models and to confirm its ability as a therapeutic potential factor in BC-LVI. This evidence concerns the gene CDCA5 and breast cancer.